FASN and cancer: AMPK activation leads to multiple anticancer outcomes: it inhibits mammalian target of rapamycin (mTOR), thereby decreasing cell proliferation and promoting apoptosis; it reduces vascular endothelial growth factor (VEGF) expression, which inhibits angiogenesis; and it suppresses fatty acid synthase (FAS), thereby limiting lipogenesis essential for cancer cell growth.